What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Enzyme
- Diabetes mellitus
Henry N. Ginsberg mainly focuses on Internal medicine, Endocrinology, Cholesterol, Diabetes mellitus and Lipoprotein.
His Internal medicine study is mostly concerned with Triglyceride, Apolipoprotein B, High-density lipoprotein, Dyslipidemia and Disease.
His Endocrinology study frequently draws connections between adjacent fields such as Statin.
Henry N. Ginsberg interconnects Niacin, Pharmacotherapy, Physiology and Blood plasma in the investigation of issues within Cholesterol.
His study looks at the intersection of Diabetes mellitus and topics like Intensive care medicine with Residual risk, Fibrate and Guideline.
His Lipoprotein research is multidisciplinary, relying on both Lipid peroxidation, Antioxidant, Vitamin E, Polyunsaturated fatty acid and Pioglitazone.
His most cited work include:
- Guidelines for the use and interpretation of assays for monitoring autophagy (3242 citations)
- Effects of combination lipid therapy in type 2 diabetes mellitus. (2012 citations)
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (1881 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Endocrinology, Apolipoprotein B, Cholesterol and Very low-density lipoprotein are his primary areas of study.
His studies deal with areas such as Diabetes mellitus and Type 2 diabetes as well as Internal medicine.
Henry N. Ginsberg works mostly in the field of Diabetes mellitus, limiting it down to topics relating to Statin and, in certain cases, Placebo and Alirocumab, as a part of the same area of interest.
Henry N. Ginsberg has included themes like Secretion, Endoplasmic reticulum, Microsomal triglyceride transfer protein and Low-density lipoprotein in his Apolipoprotein B study.
His Cholesterol research integrates issues from Saturated fatty acid, Blood plasma and Cardiology.
His Very low-density lipoprotein research incorporates themes from Catabolism, Steatosis and Apolipoprotein E.
He most often published in these fields:
- Internal medicine (78.27%)
- Endocrinology (60.45%)
- Apolipoprotein B (29.25%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (78.27%)
- Endocrinology (60.45%)
- Diabetes mellitus (17.83%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Endocrinology, Diabetes mellitus, Apolipoprotein B and Type 2 diabetes.
His study in Lipoprotein, PCSK9, Alirocumab, Statin and Lipoprotein falls under the purview of Internal medicine.
The Dyslipidemia research Henry N. Ginsberg does as part of his general Diabetes mellitus study is frequently linked to other disciplines of science, such as Gene expression, therefore creating a link between diverse domains of science.
His study in Dyslipidemia is interdisciplinary in nature, drawing from both Hypertriglyceridemia and Type 2 Diabetes Mellitus.
His biological study spans a wide range of topics, including Chylomicron, Pancreatitis and Bioinformatics.
His Type 2 diabetes research is multidisciplinary, incorporating elements of Acute coronary syndrome, Gastroenterology, Placebo, Fenofibrate and Hazard ratio.
Between 2016 and 2021, his most popular works were:
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (944 citations)
- Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants with Risk of Coronary Heart Disease (209 citations)
- NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. (150 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Enzyme
- Biochemistry
Henry N. Ginsberg spends much of his time researching Internal medicine, Apolipoprotein B, Lipoprotein, Lipoprotein and PCSK9.
The Internal medicine study combines topics in areas such as Diabetes mellitus and Endocrinology.
His study in the field of Plasma levels, Metabolism, Anacetrapib and Cholesterylester transfer protein also crosses realms of Future studies.
His studies in Apolipoprotein B integrate themes in fields like Triglyceride and Atherosclerotic cardiovascular disease.
His Lipoprotein research is multidisciplinary, incorporating perspectives in Clinical research, Secretion, Aortic valve disease, Stenosis and Disease.
Henry N. Ginsberg usually deals with PCSK9 and limits it to topics linked to Alirocumab and Kexin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
